Literature DB >> 7393514

Microinvasive carcinoma of the vulva: a clinicopathologic evaluation.

A E Barnes, J D Crissman, H F Schellhas, R S Azoury.   

Abstract

Two types of neoplasms described as superficially invasive or microinvasive carcinoma of the vulva were identified. One type, which can be treated by conservative surgery, is commonly associated with extensive overlying intraepithelial neoplasia. Usually 1 focus of microinvasion, but occasionally more invades less than 2 mm into the underlying stroma. The infiltrating cells comprise 1 or more isolated cords, and confluency is never present. The second and less common form tends to metastasize early to lymph nodes and should be treated by a radical approach. This type is seldom associated with overlying intraepithelial neoplasia. It tends to be poorly differentiated and is confluent. In this series, 2 of 3 patients with confluent microinvasion had metastases to the lymph nodes, but none of 15 patients with nonconfluent microinvasion developed metastases.

Entities:  

Mesh:

Year:  1980        PMID: 7393514

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  A fibromyxoid stromal response is associated with an infiltrative tumor morphology, perineural invasion, and lymph node metastasis in squamous cell carcinoma of the vulva.

Authors:  Susanne K Jeffus; Ashita Gehlot; Emily Holthoff; Rebecca Stone; Horace Spencer; Thomas Kelly; Steven R Post; Charles M Quick
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

2.  Pathologic features of aggressive vulvar carcinoma are associated with epithelial-mesenchymal transition.

Authors:  Emily R Holthoff; Horace Spencer; Thomas Kelly; Steven R Post; Charles M Quick
Journal:  Hum Pathol       Date:  2016-06-18       Impact factor: 3.466

Review 3.  Vulvar intraepithelial neoplasia and microinvasive carcinoma of the vulva.

Authors:  C H Buckley; E B Butler; H Fox
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.